<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Schering-Plough Corporation</title>
	<atom:link href="http://www.stockbloghub.com/tag/schering-plough-corporation/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(RX) Big Pharma and Biotech &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2009/11/09/rx-big-pharma-and-biotech-industry-outlook/20146</link>
		<comments>http://www.stockbloghub.com/2009/11/09/rx-big-pharma-and-biotech-industry-outlook/20146#comments</comments>
		<pubDate>Mon, 09 Nov 2009 23:57:38 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[IMS Health Inc.]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RX]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Schering-Plough Corporation]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20146</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health (RX), this is the main reason why global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Seretide. At the same time, new products are not expected to generate the same level of sales as the products losing patent protection have. With most of the big pharma companies already facing patent challenges for their ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/09/rx-big-pharma-and-biotech-industry-outlook/20146/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Merck and Schering-Plough Earn Merger Approval</title>
		<link>http://www.stockbloghub.com/2009/11/01/mrk-merck-and-schering-plough-earn-merger-approval/19260</link>
		<comments>http://www.stockbloghub.com/2009/11/01/mrk-merck-and-schering-plough-earn-merger-approval/19260#comments</comments>
		<pubDate>Sun, 01 Nov 2009 21:31:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Schering-Plough Corporation]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19260</guid>
		<description><![CDATA[Recently, Merck (MRK) and Schering-Plough (SGP) received approval from the US Federal Trade Commission [FTC], the Swiss Competition Commission and the Canadian Competition Bureau for their proposed merger. However, the transaction has yet to receive approval from other regulators Incorporatedluding China and Mexico. The deal was approved by the European Union antitrust regulators last week. Shareholders of both the companies have already approved the deal in August. Merck expects to close the proposed merger by year end. The FTC approval has come with the condition that both companies will sell some assets. As a result, Schering-Plough has agreed to sell its rolapitant drug, meant to be used for the treatment for nausea and vomiting in chemotherapy patients to Opko Health Inc. In addition, Merck agreed to sell its interest in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/01/mrk-merck-and-schering-plough-earn-merger-approval/19260/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRTX) Vertex Pharmaceuticals Posts Wider Loss</title>
		<link>http://www.stockbloghub.com/2009/10/27/vrtx-vertex-pharmaceuticals-posts-wider-loss/18922</link>
		<comments>http://www.stockbloghub.com/2009/10/27/vrtx-vertex-pharmaceuticals-posts-wider-loss/18922#comments</comments>
		<pubDate>Wed, 28 Oct 2009 01:40:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Schering-Plough Corporation]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18922</guid>
		<description><![CDATA[Vertex Pharmaceuticals (VRTX) posted a loss of 83 cents per share in the third quarter, 3 cents wider than the Zacks Consensus Estimate of a loss of 80 cents. The company posted a loss of 92 cents per share in the year ago period. The wider than expected loss was mainly due to a significant increase in costs and lower revenues. Revenues declined to $24.9 million in the reported quarter from $31.6 million in the year ago period. Revenues consist of royalty revenues and collaborative and other research and development revenues. Lower revenues were primarily due to a decrease in collaborative revenues. Expenses increased mainly due to the increased size of the company’s workforce Incorporatedreased spending on late-stage clinical programs and increased stock-based compensation expenses. Research and development (R&#38;D) expenses increased ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/27/vrtx-vertex-pharmaceuticals-posts-wider-loss/18922/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SGP) Schering-Plough Reports In-line Earnings</title>
		<link>http://www.stockbloghub.com/2009/10/22/sgp-schering-plough-reports-in-line-earnings/18543</link>
		<comments>http://www.stockbloghub.com/2009/10/22/sgp-schering-plough-reports-in-line-earnings/18543#comments</comments>
		<pubDate>Thu, 22 Oct 2009 22:31:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Schering-Plough Corporation]]></category>
		<category><![CDATA[SGP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18543</guid>
		<description><![CDATA[Schering-Plough Corp. (SGP) reported third-quarter earnings of 40 cents per share, which was in-line with the Zacks Consensus Estimate. Although earnings came in a cent above the year-ago level, revenues declined 2% to $4.5 billion mainly due to an unfavorable foreign exchange (Fx) impact. Operational growth of 4% was set off by a 6% Fx impact. Cholesterol franchise performance disappointed with sales declining 5% to $1.1 billion, reflecting a 2% operational decrease and a 3% unfavorable impact from Fx. U.S. sales declined 10% reflecting slowing demand. Sales in international markets increased 3%, reflecting operational growth of 10% and a 7% unfavorable impact from Fx. We believe cholesterol drugs, Zetia and Vytorin (Zetia plus simvastatin) remain under severe pressure due to disappointing clinical trial outcomes and a potential cancer risk. Results ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/22/sgp-schering-plough-reports-in-line-earnings/18543/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>($MRK) Merck Extends Galapagos Alliance</title>
		<link>http://www.stockbloghub.com/2009/10/16/mrk-merck-extends-galapagos-alliance/17822</link>
		<comments>http://www.stockbloghub.com/2009/10/16/mrk-merck-extends-galapagos-alliance/17822#comments</comments>
		<pubDate>Sat, 17 Oct 2009 00:14:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Schering-Plough Corporation]]></category>
		<category><![CDATA[SGP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17822</guid>
		<description><![CDATA[The existing alliance between Merck (MRK) and Belgian biotech company Galapagos over metabolic diseases was recently expanded to develop new therapies for atherosclerosis, or hardening of arteries due to cholesterol build-up. Following the deal, Galapagos will be eligible to receive potential milestone payments exceeding €400 million (approx $597 million). Additionally, the company will receive royalties on commercialization of the products. Merck and Galapagos entered into a diabetes and obesity drug alliance in January this year. Galapagos was eligible to receive an upfront payment of €1.5 million (approx $2.23 million) and potential milestone payments totaling €170 million (approx $253 million). Earlier, in October last year, Merck decided to terminate its late-stage obesity drug taranabant after determining that the drug was effective in high doses, which in turn triggered side effects. Merck ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/16/mrk-merck-extends-galapagos-alliance/17822/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SGP) Schering-Plough Corporation Inks Deal With Opko Health</title>
		<link>http://www.stockbloghub.com/2009/10/15/sgp-schering-plough-corporation-inks-deal-with-opko-health/17776</link>
		<comments>http://www.stockbloghub.com/2009/10/15/sgp-schering-plough-corporation-inks-deal-with-opko-health/17776#comments</comments>
		<pubDate>Thu, 15 Oct 2009 21:38:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[OPK]]></category>
		<category><![CDATA[Opko Health Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Schering-Plough Corporation]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17776</guid>
		<description><![CDATA[Recently, Schering-Plough Corporation (SGP) and Opko Health Inc. (OPK) entered into a deal which would enable Opko to acquire the assets of Schering&#8217;s neurokinin-1 (NK-1) receptor antagonist program. The companies did not disclose the terms of the agreement. NK-1 receptors are mostly found in the brain. However, they are also found in other tissues of the body. Their activation causes a release of neurotransmitters and other signaling molecules that play a key role in controlling nausea and vomiting amongst other functions. The U.S. market for nausea and vomiting drugs is estimated to be in excess of $2 billion. Rolapitant, Schering&#8217;s lead neurokinin, recently completed mid-stage studies for the prevention of nausea and vomiting due to cancer chemotherapy, surgery and other indications. The company has initiated early-stage studies for another compound ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/15/sgp-schering-plough-corporation-inks-deal-with-opko-health/17776/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SEPR) Dainippon-Sepracor Deal Emerges</title>
		<link>http://www.stockbloghub.com/2009/10/15/sepr-dainippon-sepracor-deal-emerges/17778</link>
		<comments>http://www.stockbloghub.com/2009/10/15/sepr-dainippon-sepracor-deal-emerges/17778#comments</comments>
		<pubDate>Thu, 15 Oct 2009 21:17:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Schering-Plough Corporation]]></category>
		<category><![CDATA[SEPR]]></category>
		<category><![CDATA[Sepracor]]></category>
		<category><![CDATA[SGP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17778</guid>
		<description><![CDATA[Today, Dainippon Sumitomo and Sepracor (SEPR) have announced the successful completion of the initial share offering period, where almost 78.2% of Sepracor’s shares were tendered. The offer period has been extended to Oct 19, 2009, to enable other shareholders to tender their shares as well. As a reminder, in September, the Japanese pharmaceutical company Dainippon Sumitomo Pharma Co had announced a deal to acquire Sepracor at $23 per share or $2.6 billion. However, soon after the announcement, shareholders of Sepracor filed a suit in a Delaware court against the company, citing the offered price as inadequate. They were seeking the court’s intervention to stop the deal and pay damages. Additionally, certain aspects of the deal were against the interest of Sepracor’s shareholders. The deal included a $77.4 million termination fee ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/15/sepr-dainippon-sepracor-deal-emerges/17778/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SNTS) Santarus Signs Deal with Norgine</title>
		<link>http://www.stockbloghub.com/2009/10/13/snts-santarus-signs-deal-with-norgine/17486</link>
		<comments>http://www.stockbloghub.com/2009/10/13/snts-santarus-signs-deal-with-norgine/17486#comments</comments>
		<pubDate>Tue, 13 Oct 2009 19:45:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Santarus Inc]]></category>
		<category><![CDATA[Schering-Plough Corporation]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[SNTS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17486</guid>
		<description><![CDATA[This morning, Santarus, Inc. (SNTS) entered into a licensing agreement with Norgine B.V., a European specialty pharmaceutical company. Under the licensing agreement, Norgine has been granted exclusive rights for the development, manufacture and commercialization of prescription immediate-release Zegerid products incorporating the proton pump inhibitor (PPI) omeprazole in combination with one or more buffering agents in specified markets in Western, Central and Eastern Europe. As per the terms of the agreement, Santarus will receive an upfront fee of $2.5 million. Moreover, Santarus will be entitled to receive up to $10 million in milestone payments based on the achievement of certain regulatory events, subject to certain reductions based on actual out-of pocket costs incurred by Norgine for the product. Santarus will also receive tiered royalties in the mid- to high-teens range on ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/13/snts-santarus-signs-deal-with-norgine/17486/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENZN) Enzon Pharma Announces European Approval for Cimzia</title>
		<link>http://www.stockbloghub.com/2009/10/08/enzn-enzon-pharma-announces-european-approval-for-cimzia/17197</link>
		<comments>http://www.stockbloghub.com/2009/10/08/enzn-enzon-pharma-announces-european-approval-for-cimzia/17197#comments</comments>
		<pubDate>Thu, 08 Oct 2009 19:10:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ENZN]]></category>
		<category><![CDATA[Enzon Pharmaceuticals Inc]]></category>
		<category><![CDATA[OSI Pharmaceuticals Inc]]></category>
		<category><![CDATA[OSIP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Schering-Plough Corporation]]></category>
		<category><![CDATA[SGP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17197</guid>
		<description><![CDATA[Yesterday, Enzon Pharma (ENZN) announced the European Commission approval of UCB’s Cimzia (certolizumab pegol) for the treatment of adult patients with moderate-to-severe active rheumatoid arthritis (RA). Cimzia utilizes Enzon&#8217;s PEGylation technology. Earlier in May 2009, Cimzia received the US Food and Drug Administration&#8217;s (FDA) approval. Apart from RA, the drug is used to treat Crohn’s disease. Cimzia is a PEGylated anti-TNFa &#8211; Tumor Necrosis Factor alpha. Enzon receives royalties from several drugs manufactured using this technology – Schering Plough’s (SGP) Pegintron, Macugen marketed by Pfizer (PFE) and OSI Pharmaceuticals (OSIP) and Roche’s Pegasys. We believe the approval of Cimzia will boost its sales, thereby increasing the royalty income for Enzon. In a positive development, earlier this week, an FDA advisory panel voted in favor of recommending Pegintron as a treatment in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/08/enzn-enzon-pharma-announces-european-approval-for-cimzia/17197/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SGP) Schering-Plough and Johnson &amp; Johnson Score European Union Drug Approval</title>
		<link>http://www.stockbloghub.com/2009/10/07/sgp-schering-plough-and-johnson-johnson-score-european-union-drug-approval/17092</link>
		<comments>http://www.stockbloghub.com/2009/10/07/sgp-schering-plough-and-johnson-johnson-score-european-union-drug-approval/17092#comments</comments>
		<pubDate>Wed, 07 Oct 2009 19:42:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Schering-Plough Corporation]]></category>
		<category><![CDATA[SGP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17092</guid>
		<description><![CDATA[Yesterday, Schering-Plough Corp. (SGP) and Johnson &#38; Johnson (JNJ) announced the approval of their drug Simponi (golimumab) in the European Union for the treatment of rheumatoid arthritis and other immune system disorders. The drug was approved by the U.S. Food and Drug Administration (FDA) in April 2009. As a reminder, Schering acquired co-development rights to Simponi in the third quarter of 2005 from Johnson &#38; Johnson’s biotech arm, Centocor Inc., which had developed and discovered the drug. Johnson &#38; Johnson enjoys exclusive marketing rights of Simponi in the U.S., while Schering-Plough holds marketing rights outside the U.S.  excluding Japan, Indonesia and Taiwan where the drug will be co-marketed with other vendors subsequent to regulatory approvals. Simponi, a next-generation, fully human, anti-tumor necrosis factor (TNF), received European approval as a once-a-month ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/07/sgp-schering-plough-and-johnson-johnson-score-european-union-drug-approval/17092/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Merck Seeks European Union Approval of its Schering-Plough Purchase</title>
		<link>http://www.stockbloghub.com/2009/09/23/mrk-merck-seeks-european-union-approval-of-its-schering-plough-purchase/15910</link>
		<comments>http://www.stockbloghub.com/2009/09/23/mrk-merck-seeks-european-union-approval-of-its-schering-plough-purchase/15910#comments</comments>
		<pubDate>Wed, 23 Sep 2009 19:25:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Schering-Plough Corporation]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15910</guid>
		<description><![CDATA[Yesterday, Merck &#38; Co. (MRK) announced that it is seeking approval from the European Union (EU) for its $41.1 billion acquisition of Schering-Plough Corp. (SGP). The regulatory authorities in the EU are expected to pass a verdict on the matter by Oct. 23. Merck filed for approval of the merger in the EU after the completion of the sale of its 50% interest in animal health company Merial Limited (Merial) to Sanofi-Aventis (SNY) for a cash consideration of $4 billion ( US ). As a reminder, Merial was founded in 1997. It was a 50/50 joint venture between Merck and Sanofi-Aventis and is now a wholly owned subsidiary of the latter. In 2008, Merial was ranked third in the animal health market, with a market share estimated at 13.8% and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/23/mrk-merck-seeks-european-union-approval-of-its-schering-plough-purchase/15910/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

